Athena Cardionet Ltd.
Sector: Biotechnology - Therapeutics
Medical Field: Cardiovascular
Technological Field: Metal Chelators and Complexes
Year Established: 1998
Athena Cardionet Ltd. is an emerging pharmaceutical company focusing on inhibition of metal ion dependent pathological processes; prevention of ischemia-reperfusion injuries and metalloprotease activity. The company offers comprehensive therapeutic and technological answers in cell, tissue, and organ preservation, neurotrauma and stroke. Its unique technology includes patented use of non-toxic concentrations of YAC101, a heavy metal chelator, as well as several other patent pending specific novel chelator complexes.
Athena Cardionet is already advanced in developing patent proof pharmaceutical means to protect the heart and other organs in preservation and under operation. The company already has promising experimental data showing that the company will be able to use YAC-101 and its' complexes to inactivate zinc-dependent matalloproteases involved in metastasis and angiogenesis, as well as metalloproteases of bacterial origin.